The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

VI.b

Pulmonary arterial hypertension

Publications

Montani D, Antigny F, Jutant EM, Chaumais MC, Le Ribeuz H, Grynblat J, Khouri C, Humbert M

Pulmonary hypertension associated with diazoxide: the SUR1 paradox.

ERJ open research. 2023;9(6)

Thornton P, Truong L, Reynolds C, Hamby T, Nedrelow J

Rate of Serious Adverse Events Associated with Diazoxide Treatment of Patients with Hyperinsulinism.

Hormone research in paediatrics. 2019;91(1):25-32

Timlin MR, Black AB, Delaney HM, Matos RI, Percival CS

Development of Pulmonary Hypertension During Treatment with Diazoxide: A Case Series and Literature Review.

Pediatric cardiology. 2017;38(6):1247-1250

Demirel F, Unal S, Çetin II, Esen I, Arasli A

Pulmonary hypertension and reopening of the ductus arteriosus in an infant treated with diazoxide.

Journal of pediatric endocrinology & metabolism : JPEM. 2011;24(7-8):603-5